GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » ROIC %

Antares Pharma (Antares Pharma) ROIC % : -5.81% (As of Mar. 2022)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Antares Pharma's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2022 was -5.81%.

As of today (2024-04-25), Antares Pharma's WACC % is 10.88%. Antares Pharma's ROIC % is 11.53% (calculated using TTM income statement data). Antares Pharma generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Antares Pharma ROIC % Historical Data

The historical data trend for Antares Pharma's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma ROIC % Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.06 -38.57 1.78 83.77 15.28

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.44 27.08 20.12 16.15 -5.81

Competitive Comparison of Antares Pharma's ROIC %

For the Medical Instruments & Supplies subindustry, Antares Pharma's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's ROIC % distribution charts can be found below:

* The bar in red indicates where Antares Pharma's ROIC % falls into.



Antares Pharma ROIC % Calculation

Antares Pharma's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2021 is calculated as:

ROIC % (A: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2020 ) + Invested Capital (A: Dec. 2021 ))/ count )
=27.342 * ( 1 - 25.67% )/( (122.12 + 143.896)/ 2 )
=20.3233086/133.008
=15.28 %

where

Antares Pharma's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2022 is calculated as:

ROIC % (Q: Mar. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2021 ) + Invested Capital (Q: Mar. 2022 ))/ count )
=-11.28 * ( 1 - 26.04% )/( (143.896 + 143.351)/ 2 )
=-8.342688/143.6235
=-5.81 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antares Pharma  (NAS:ATRS) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Antares Pharma's WACC % is 10.88%. Antares Pharma's ROIC % is 11.53% (calculated using TTM income statement data). Antares Pharma generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Antares Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Antares Pharma ROIC % Related Terms

Thank you for viewing the detailed overview of Antares Pharma's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447